Direct Factor Xa and direct thrombin inhibitors: A clinical trial update

被引：0
|
作者：
Turpie, Alexander G. G. [1 ]
机构：
[1] McMaster Univ, Hamilton, ON L8L 2X2, Canada
来源：
CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT | 2009年 / 12卷 / 04期
关键词：
Anticoagulant; clinical trial; oral; ORAL DIRECT THROMBIN; MOLECULAR-WEIGHT HEPARIN; TOTAL HIP-REPLACEMENT; DEEP-VEIN THROMBOSIS; RIVAROXABAN BAY 59-7939; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM; DABIGATRAN ETEXILATE; ANTITHROMBOTIC THERAPY; DOUBLE-BLIND;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Anticoagulant use is recommended for the prevention and treatment of several thromboembolic disorders including venous thromboembolism. However, anticoagulants are often underprescribed because of the disadvantages associated with conventional agents, including the requirement for routine clinical monitoring and parenteral administration. Recent research has focused on the development of agents that target specific factors in the coagulation cascade, primarily Factor (F)Xa and thrombin. There are several new, targeted oral anticoagulants in development that could potentially provide more effective and more convenient anticoagulation than conventional agents. This review provides an update on clinical trials of the direct FXa and thrombin inhibitors.
引用
收藏
页码：497 / 508
页数：12
相关论文
共 50 条
  • [21] Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa
    Bauer, K. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 259 - 259
  • [22] Direct thrombin and factor Xa inhibitors in children: A quest for new anticoagulants for children
    Streif W.
    Ageno W.
    Wiener Medizinische Wochenschrift, 2011, 161 (3-4) : 73 - 79
  • [23] Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development
    Bengt I. Eriksson
    Daniel J. Quinlan
    Jeffrey I. Weitz
    Clinical Pharmacokinetics, 2009, 48 : 1 - 22
  • [24] Oral Direct Factor Xa Inhibitors
    Yeh, Calvin H.
    Fredenburgh, James C.
    Weitz, Jeffrey I.
    CIRCULATION RESEARCH, 2012, 111 (08) : 1069 - 1078
  • [25] Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis
    Robertson, Lindsay
    Kesteven, Patrick
    McCaslin, James E.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (06):
  • [26] Surgery and invasive procedures in patients on long term treatment with oral direct thrombin or factor Xa inhibitors (update 2012)
    Sie, Pierre
    Samama, Charles Marc
    Godier, Anne
    Rosencher, Nadia
    Steib, Annick
    Llau, Juan V.
    van der Linden, Philippe
    Pernod, Gilles
    Lecompte, Thomas
    Gouin-Thibault, Isabelle
    Albaladejo, Pierre
    SANG THROMBOSE VAISSEAUX, 2012, 24 (06): : 269 - 278
  • [27] The king is dead (warfarin): direct thrombin and factor Xa inhibitors: the next Diadochian War?
    Diener, Hans-Christoph
    Eikelboom, John
    Granger, Christopher B.
    Hacke, Werner
    INTERNATIONAL JOURNAL OF STROKE, 2012, 7 (02) : 139 - 141
  • [28] Mechanism Of Peak Protraction In Thrombin Generation After Administration Of Direct Factor Xa Inhibitors
    Bloemen, Saartje
    De Laat, Bas
    Hemker, H. Coenraad
    Al Dieri, Raed
    BLOOD, 2013, 122 (21)
  • [29] Oral, Direct Thrombin and Factor Xa Inhibitors: The Replacement for Warfarin, Leeches, and Pig Intestines?
    Straub, Alexander
    Roehrig, Susanne
    Hillisch, Alexander
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2011, 50 (20) : 4574 - 4590
  • [30] Safety and Efficacy of New Oral Direct Inhibitors of Thrombin and Factor Xa in Antiphospholipid Syndrome
    Noel, Nicolas
    Dutasta, Fabien
    Costedoat-Chalumeau, Nathalie
    Bienvenu, Boris
    Mariette, Xavier
    Geffray, Loik
    Sene, Damien
    Michot, Jean-Marie
    Fain, Olivier
    Darnige, Luc
    Ankri, Annick
    Cacoub, Patrice
    Piette, Jean-Charles
    Saadoun, David
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S4 - S5
12345